Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin

Journal of Clinical Pharmacology

Volumn 39, Issue 8, 1999, Pages 847-854

  Weber, C ^a   Banken, L ^a   Birnboeck, H ^a   Schulz, R ^a  

^a Department of Clinical Pharmacology ^*  (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7; BOSENTAN; CYTOCHROME P450 3A4; ENDOTHELIN RECEPTOR ANTAGONIST; WARFARIN;

ADULT; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; STEREOCHEMISTRY;

EID: 0033338133     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922008380     Document Type: Article

References (19)

1. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
2. Endothelin and endothelin antagonists: Potential role in cardiovascular and renal disease
3. Endothelin: New discoveries and rapid progress in clinic
4. Pharmacological characterisation of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist
5. The effect of an endothelin receptor antagonist, bosentan, on blood pressure in patients with essential hypertension
6. Evidence of endothelin-1 mediated vasoconstriction in severe chronic heart failure
7. Short-term endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure
8. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects
9. Multiple dose pharmacokinetics, safety and tolerability of bosentan, an orally active endothelin receptor antagonist in healthy male volunteers
10. Bosentan, a new endothelin-receptor antagonist: Prediction of the systemic plasma clearance in man from combined in vivo and in vitro data
11. Anticoagulant, thrombolytic, and antiplatelet drugs
12. Clinically important drug interactions with anticoagulants: An update
13. Stereochemical aspects of warfarin drug interactions: Use of a combined pharmacokinetic-pharmacodynamic model
14. Human P450 metabolism of warfarin
15. The warfarin-cimetidine interaction: Stereochemical considerations
16. Phenylbutazonewarfarin interaction in man: Further stereochemical and metabolic considerations
17. Stereospecific fluorescence high-performance liquid chromatography analysis of (R)- and (S)-warfarin and its metabolites in plasma and urine
18. The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers
19. Population pharmacokinetics and pharmacodynamics of warfarin in healthy young adults